Since 2B4 and NKp46 are already being used as transmembrane domains for CAR-NK structuring, and CS1 and 2B4 have shown promising results in CAR-T and CAR-NK immunotherapy, further studies are warranted to assess the functional role of these receptors, especially LLT1 in a larger cohort of ALL subjects to develop an immunotherapeutic alternative for childhood ALL. This evidence concerns the gene CLEC2D and acute lymphoblastic leukemia.